Orexigen Therapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

OREX 4.76 -0.01 (-0.10%)
price chart
Orexigen Therapeutics Inc (NASDAQ:OREX) in Focus
[EDGAR] Orexigen Therapeutics Inc (NASDAQ:OREX)(TREND ANALYSIS) entered into a Separation and Consulting Agreement (the “Separation Agreement”) with Heather D. Turner in connection with Ms. Turner's resignation, effective June 25, 2015 (the ...
Company Shares of Orexigen Therapeutics, Inc. Rally 0.21%  Insider Trading Report
Tues Pre-Market Information: Internet Initiative Japan Inc. (IIJI), Orexigen ...  WallStreet Scope
Why Orexigen Therapeutics, Inc. Lost a Quarter of Its Value in May
What: Shares of Orexigen Therapeutics (NASDAQ:OREX), a small-cap drug developer focused on treating obesity, slimmed down and lost 25% of its value in May, based on data from S&P Capital IQ, after announcing bad news regarding its long-term ...
Orexigen Therapeutics, Inc. Goes From Biotech Beauty to Dreadful Drugmaker
Orexigen Therapeutics (NASDAQ:OREX) has been the darling of the obesity drugmakers, doing something Arena Pharmaceuticals (NASDAQ:ARNA) and VIVUS (NASDAQ:VVUS) weren't able to do: keep its share price above where it was when its ...
West Coast Biotech Roundup: Orexigen, Denali, Nant, ASCO & More  Xconomy
Biogen Inc, Gilead Sciences, Inc., Orexigen Therapeutics, Inc.: Best Biotech ...
“Earlier, Biogen had initiated a project with Fitbit, using the company's activity trackers to gather data on MS patients,” Money Morning's Defense and Tech Specialist Michael Robinson said.
Ford Motor Company, Orexigen Therapeutics, Inc., Altria Group Inc: Cheap ...
2: Orexigen Therapeutics (Nasdaq: OREX). Orexigen Therapeutics Inc. (Nasdaq: OREX) is on our cheap stocks to buy now list because it's trading near $5 per share.
Analysts Views: Orexigen Therapeutics, Inc. (NASDAQ:OREX)  Markets Daily
Why It's Lights Out for Orexigen Therapeutics, Inc.
What: Shares of Orexigen Therapeutics (NASDAQ:OREX), a biopharmaceutical company focused on developing therapies to treat obesity, saw its own valuation slim down by as much as 13% during Tuesday's trading session after it and its partner Takeda ...
Orexigen Therapeutics Provides Statement on Termination of the Light Study ...  MarketWatch
Takeda Threatens to End Orexigen Partnership as Study Halted  Bloomberg
Why Orexigen Therapeutics, Inc. Lost a Sixth of Its Value in April
What: Shares of Orexigen Therapeutics (NASDAQ:OREX), a biopharmaceutical company engaged in the development of therapies for chronic weight management, lost 16% in April, or a sixth of its market value according to data from S&P Capital IQ, after it ...
Orexigen Therapeutics Inc (NASDAQ:OREX) in Spotlight  Street Report
Foresite Capital Betting It All On These Four Healthcare Stocks  Insider Monkey (blog)
Analytic Report on Orexigen Therapeutics Inc (NASDAQ:OREX)
[PRNewswire] Orexigen Therapeutics Inc (NASDAQ:OREX)(TREND ANALYSIS) announced that two Contrave´┐Ż (naltrexone HCI and bupropion HCI) abstracts will be presented at the upcoming annual meeting of the American Diabetes Association being ...
Company Shares of Orexigen Therapeutics, Inc. Rally 4.8%  News Watch International
Wall Street Has $12.2 Price Target on Orexigen Therapeutics, Inc. (NASDAQ ...  Markets Daily
Orexigen Therapeutics, Inc. Gives the Skinny on Its Drug Launch
The launch of Orexigen Therapeutics' (NASDAQ:OREX) obesity drug Contrave was nothing to get too excited about. In the fourth quarter, which included 10 weeks of the launch, net sales of the drug were just $6.5 million, which resulted in $1.3 million in ...
UPDATE: Orexigen Therapeutics Shares Drop After Q4 Results  Benzinga
Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and ...  PR Newswire (press release)
Why Orexigen Therapeutics, Inc. (OREX), Gap Inc. (GPS) and Rackspace ...
Orexigen185 Why Orexigen Therapeutics, Inc. (OREX), Gap Inc. (GPS The ink didn't even have a chance to fully dry on last week's encouraging first quarter earnings report from Orexigen Therapeutics before Murphy's Law kicked in and upended OREX ...
Stock's Negative Trend: Interphase (NASDAQ:INPH), Orexigen Therapeutics ...  wsnewspublishers
Orexigen Plummets After Release Of 50% Interim Results, But Is This The End?  Seeking Alpha